Science News
from research organizations

Researchers identify two HIV-1 envelope immunogens capable of eliciting antibodies associated with vaccine protection

Date:
January 24, 2014
Source:
Seattle Biomedical Research Institute (Seattle BioMed)
Summary:
Researchers identified two HIV-1 Envelope immunogens that elicit broadly neutralizing antibodies when introduced as a vaccine.
Share:
       
FULL STORY

Seattle BioMed researchers identified two HIV-1 Envelope immunogens that elicit broadly neutralizing antibodies when introduced as a vaccine. The study was published online in PLOS One.

The HIV-1 Envelope protein immunogens were derived from an elite neutralizer, an individual with an unusually potent antibody response effective against the majority of HIV subtypes. Seattle BioMed researchers identified two Envelope immunogens that elicited cross-reactive binding antibodies to the variable regions 1 and 2 (V1V2) region of the envelope protein and induced antibodies capable of neutralizing an array of HIV from different subtypes.

"Previous studies have shown that anti-HIV-1 neutralizing antibodies can effectively block infection with HIV-1 if present prior to infection with the virus," said Noah Sather, Ph.D. principal scientist at Seattle BioMed and corresponding author of the study. "In addition, antibodies that target a specific part of the Envelope protein, the V1V2 region, have been shown in clinical trials to be associated with a reduced risk of infection. Thus, the ideal vaccine would introduce immunogens that elicit antibodies both targeted to the V1V2 region of the Envelope protein and capable of providing protection from a wide variety of HIV-1 subtypes."

Follow on studies will focus on further modifying the Envelope immunogens to increase the potency and effectiveness of the vaccine.

The HIV-1 epidemic remains a significant threat to global health, with 2.3 million new HIV-1 infections and 1.6 million AIDS-related deaths each year. While access to anti-retroviral therapies has increased, the best route of defeating the epidemic is still a universally effective HIV-1 vaccine.


Story Source:

The above post is reprinted from materials provided by Seattle Biomedical Research Institute (Seattle BioMed). Note: Materials may be edited for content and length.


Journal Reference:

  1. Sara Carbonetti, Brian G. Oliver, Jolene Glenn, Leonidas Stamatatos, D. Noah Sather. Soluble HIV-1 Envelope Immunogens Derived from an Elite Neutralizer Elicit Cross-Reactive V1V2 Antibodies and Low Potency Neutralizing Antibodies. PLoS ONE, 2014; 9 (1): e86905 DOI: 10.1371/journal.pone.0086905

Cite This Page:

Seattle Biomedical Research Institute (Seattle BioMed). "Researchers identify two HIV-1 envelope immunogens capable of eliciting antibodies associated with vaccine protection." ScienceDaily. ScienceDaily, 24 January 2014. <www.sciencedaily.com/releases/2014/01/140124101737.htm>.
Seattle Biomedical Research Institute (Seattle BioMed). (2014, January 24). Researchers identify two HIV-1 envelope immunogens capable of eliciting antibodies associated with vaccine protection. ScienceDaily. Retrieved July 6, 2015 from www.sciencedaily.com/releases/2014/01/140124101737.htm
Seattle Biomedical Research Institute (Seattle BioMed). "Researchers identify two HIV-1 envelope immunogens capable of eliciting antibodies associated with vaccine protection." ScienceDaily. www.sciencedaily.com/releases/2014/01/140124101737.htm (accessed July 6, 2015).

Share This Page: